Cero Therapeutics Holdings, Inc. (CERO): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$16.10M

Year ended 2025-12-31

-$12.12M

Trailing 12 months to 2026-06-30

2022-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$16.10M	n/a	2026-04-15, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31	-$1.52M	n/m	2024-04-02, From 2023-01-01
2022-12-31	-$1.09M	n/a	2024-04-02, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Cero Therapeutics Holdings, Inc. (CERO)	2025-12-31	-$16.10M	n/a
BioCardia, Inc. (BCDA)	2025-12-31	-$7.44M	n/m
Estrella Immunopharma, Inc. (ESLA)	2025-12-31	-$1.79M	n/a
Tevogen Inc. (TVGN)	2025-12-31	-$12.33M	n/m
Eloxx Pharmaceuticals, Inc. (ELOX)	2025-12-31	-$6.33M	n/m
AIM ImmunoTech Inc. (AIM)	2025-12-31	-$10.96M	n/m
Exozymes Inc. (EXOZ)	2025-12-31	-$6.50M	n/m
Silexion Therapeutics Corp (SLXN)	2025-12-31	-$10.82M	n/m
VivoSim Labs, Inc. (VIVS)	2026-03-31	-$10.83M	n/m

Compare CERO, BCDA, ESLA, TVGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗